Benralizumab Shows Promise in Rare Eosinophilic Disorders Beyond Asthma, Study Finds

A prospective study from Hadassah Medical Center (搜索)搜索该词条 has demonstrated that benralizumab查看药品详情, an anti-IL-5 receptor (搜索)搜索该靶点 monoclonal antibody, shows significant efficacy in treating rare eosinophilic disorders (搜索)搜索该疾病 beyond its approved indications for severe eosinophilic asthma (搜索)搜索该疾病 and eosinophilic granulomatosis with polyangiitis (搜索)搜索该疾病 (EGPA (搜索)搜索该疾病).

The single-center, open-label study enrolled 19 adults with diverse eosinophilic diseases, with 17 patients initiating treatment with benralizumab查看药品详情 30 mg administered subcutaneously every 4 weeks for 24 weeks. Responders continued treatment for a full 52 weeks.

Remarkable Clinical Outcomes

The results exceeded expectations, with 16 of 17 patients achieving clinical resolution based on the primary endpoint of at least 50% reduction in peripheral eosinophil counts or tissue infiltration. All patients demonstrated complete peripheral eosinophil depletion, a finding that underscores the drug's potent mechanism of action.

Perhaps most significantly for patient quality of life, corticosteroids were successfully discontinued in all patients who completed the study. This represents a major therapeutic advance, as chronic corticosteroid use carries substantial long-term risks including bone loss, diabetes, and immunosuppression.

Broad Therapeutic Spectrum

The study's strength lies in its demonstration of efficacy across a heterogeneous group of rare eosinophilic conditions. Patients with eosinophilic leukemia (搜索)搜索该疾病, folliculitis (搜索)搜索该疾病, vaginitis (搜索)搜索该疾病, and IgG4-related disease (搜索)搜索该疾病 all responded to treatment, suggesting benralizumab查看药品详情's therapeutic potential extends well beyond its current approved indications.

Only one patient had a partial response, while another discontinued treatment due to a mild, unrelated liver enzyme elevation. Importantly, no serious adverse events were attributed to benralizumab查看药品详情 during the study period.

Treatment Durability Concerns

The researchers noted that relapses were observed after treatment cessation, indicating that ongoing therapy may be necessary to maintain clinical benefits. This finding aligns with the chronic nature of these eosinophilic disorders (搜索)搜索该疾病 and suggests that benralizumab查看药品详情 may need to be considered as a long-term maintenance therapy.

Expanding to Pediatric Populations

Building on these promising adult data, AstraZeneca查看公司主页 has initiated a pediatric basket trial (D3255C00004) to evaluate benralizumab查看药品详情 in children with rare eosinophilic diseases. The open-label, multicenter study will initially focus on pediatric participants with EGPA (搜索)搜索该疾病, with plans to add additional cohorts for other eosinophilic diseases in future protocol amendments.

The pediatric trial features a 52-week open-label treatment period followed by an extension period of at least 52 additional weeks, allowing for comprehensive long-term safety and efficacy assessment in this vulnerable population.

Clinical Implications

These findings address a significant unmet medical need in the management of rare eosinophilic disorders (搜索)搜索该疾病, which have historically been challenging to treat due to their heterogeneity and lack of targeted therapies. The ability to achieve corticosteroid-free disease control represents a paradigm shift in treatment approach for these conditions.

The researchers concluded that benralizumab查看药品详情 was safe, well tolerated, and effective across diverse rare eosinophilic disorders (搜索)搜索该疾病, supporting its broader therapeutic potential and warranting further investigation in larger, controlled studies.